The myeloid transcription factor GATA-2 regulates the viral UL144 gene during human cytomegalovirus latency in an isolate-specific manner

Journal of Virology

Volumn 87, Issue 8, 2013, Pages 4261-4271

  Poole, Emma ^a   Walther, Anett ^a   Raven, Kathy ^a   Benedict, Christopher A ^b   Mason, Gavin M ^a   Sinclair, John ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; CD34 ANTIGEN; TRANSCRIPTION FACTOR GATA 4; UL144 PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ARTICLE; BINDING AFFINITY; BINDING SITE; CELL TYPE; CONTROLLED STUDY; GENE; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN CELL; LUNA GENE; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; UL144 GENE; VIRUS GENE; VIRUS ISOLATION; VIRUS LATENCY;

ANTIGENS, CD14; ANTIGENS, CD34; CYTOMEGALOVIRUS; GATA2 TRANSCRIPTION FACTOR; HOST-PATHOGEN INTERACTIONS; HUMANS; MEMBRANE GLYCOPROTEINS; MONOCYTES; VIRAL PROTEINS; VIRUS LATENCY;

HUMAN HERPESVIRUS 5;

EID: 84875797276     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03497-12     Document Type: Article

References (69)

1. Rubin RH. 1990. Impact of cytomegalovirus infection on organ transplant recipients. Rev. Infect. Dis. 12(Suppl 7):S754-S766.
2. Cheung AK, Abendroth A, Cunningham AL, Slobedman B. 2006. Viral gene expression during the establishment of human cytomegalovirus latent infection in myeloid progenitor cells. Blood 108:3691-3699.
3. + bone marrow progenitors. J. Gen. Virol. 77(Part 12):3099-3102.
4. Sinclair J. 2008. Human cytomegalovirus: latency and reactivation in the myeloid lineage. J. Clin. Virol. 41:180-185.
5. Stern JL, Slobedman B. 2008. Human cytomegalovirus latent infection of myeloid cells directs monocyte migration by up-regulating monocyte chemotactic protein-1. J. Immunol. 180:6577-6585.
6. Hahn G, Jores R, Mocarski ES. 1998. Cytomegalovirus remains latent in a common precursor of dendritic and myeloid cells. Proc. Natl. Acad. Sci. U. S. A. 95:3937-3942.
7. + monocytes. Proc. Natl. Acad. Sci. U. S. A. 107:20039-20044.
8. Kondo K, Kaneshima H, Mocarski ES. 1994. Human cytomegalovirus latent infection of granulocyte-macrophage progenitors. Proc. Natl. Acad. Sci. U. S. A. 91:11879-11883.
9. Reeves MB, Lehner PJ, Sissons JG, Sinclair JH. 2005. An in vitro model for the regulation of human cytomegalovirus latency and reactivation in dendritic cells by chromatin remodelling. J. Gen. Virol. 86:2949-2954.
10. Reeves MB, MacAry PA, Lehner PJ, Sissons JG, Sinclair JH. 2005. Latency, chromatin remodeling, and reactivation of human cytomegalovirus in the dendritic cells of healthy carriers. Proc. Natl. Acad. Sci. U. S. A. 102:4140-4145.
11. Reeves MB, Sinclair JH. 2010. Analysis of latent viral gene expression in natural and experimental latency models of human cytomegalovirus and its correlation with histone modifications at a latent promoter. J. Gen. Virol. 91:599-604.
12. Sinclair J, Sissons P. 2006. Latency and reactivation of human cytomegalovirus. J. Gen. Virol. 87:1763-1779.
13. Soderberg-Naucler C, Fish KN, Nelson JA. 1997. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell 91:119-126.
14. Goodrum FD, Jordan CT, High K, Shenk T. 2002. Human cytomegalovirus gene expression during infection of primary hematopoietic progenitor cells: a model for latency. Proc. Natl. Acad. Sci. U. S. A. 99:16255-16260.
15. Kondo K, Mocarski ES. 1995. Cytomegalovirus latency and latencyspecific transcription in hematopoietic progenitors. Scand. J. Infect. Dis. Suppl. 99:63-67.
16. Kondo K, Xu J, Mocarski ES. 1996. Human cytomegalovirus latent gene expression in granulocyte-macrophage progenitors in culture and in seropositive individuals. Proc. Natl. Acad. Sci. U. S. A. 93:11137-11142.
17. Jenkins C, Abendroth A, Slobedman B. 2004. A novel viral transcript with homology to human interleukin-10 is expressed during latent human cytomegalovirus infection. J. Virol. 78:1440-1447.
18. Goodrum F, Reeves M, Sinclair J, High K, Shenk T. 2007. Human cytomegalovirus sequences expressed in latently infected individuals promote a latent infection in vitro. Blood 110:937-945.
19. Bego M, Maciejewski J, Khaiboullina S, Pari G, St Jeor S. 2005. Characterization of an antisense transcript spanning the UL81-82 locus of human cytomegalovirus. J. Virol. 79:11022-11034.
20. +) cytotoxic T cells. Invest. Ophthalmol. Vis. Sci. 44:665-671.
21. Falk CS, Mach M, Schendel DJ, Weiss EH, Hilgert I, Hahn G. 2002. NK cell activity during human cytomegalovirus infection is dominated by US2-11-mediated HLA class I down-regulation. J. Immunol. 169:3257-3266.
22. + NK cells in response to human cytomegalovirus-infected fibroblasts. Blood 107:3624-3631.
23. Powers CJ, Fruh K. 2008. Signal peptide-dependent inhibition of MHC class I heavy chain translation by rhesus cytomegalovirus. PLoS Pathog. 4:e1000150. doi:10.1371/journal.ppat.1000150.
24. +T-cell migration and suppression of effector function. Proc. Natl. Acad. Sci. U. S. A.
25. Cha TA, Tom E, Kemble GW, Duke GM, Mocarski ES, Spaete RR. 1996. Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains. J. Virol. 70:78-83.
26. Le VT, Trilling M, Hengel H. 2011. The cytomegaloviral protein pUL138 acts as potentiator of tumor necrosis factor (TNF) receptor 1 surface density to enhance ULb=-encoded modulation of TNF-alpha signaling. J. Virol. 85:13260-13270.
27. Montag C, Wagner JA, Gruska I, Vetter B, Wiebusch L, Hagemeier C. 2011. The latency-associated UL138 gene product of human cytomegalovirus sensitizes cells to tumor necrosis factor alpha (TNF-alpha) signaling by upregulating TNF-alpha receptor 1 cell surface expression. J. Virol. 85:11409-11421.
28. Poole E, Atkins E, Nakayama T, Yoshie O, Groves I, Alcami A, Sinclair J. 2008. NF-kappaB-mediated activation of the chemokine CCL22 by the product of the human cytomegalovirus gene UL144 escapes regulation by viral IE86. J. Virol. 82:4250-4256.
29. Poole E, Groves I, MacDonald A, Pang Y, Alcami A, Sinclair J. 2009. Identification of TRIM23 as a cofactor involved in the regulation of NFkappaB by human cytomegalovirus. J. Virol. 83:3581-3590.
30. Poole E, King CA, Sinclair JH, Alcami A. 2006. The UL144 gene product of human cytomegalovirus activates NFkappaB via a TRAF6-dependent mechanism. EMBO J. 25:4390-4399.
31. Wilkinson GW, Tomasec P, Stanton RJ, Armstrong M, Prod'homme V, Aicheler R, McSharry BP, Rickards CR, Cochrane D, Llewellyn-Lacey S, Wang EC, Griffin CA, Davison AJ. 2008. Modulation of natural killer cells by human cytomegalovirus. J. Clin. Virol. 41:206-212.
32. Wills MR, Ashiru O, Reeves MB, Okecha G, Trowsdale J, Tomasec P, Wilkinson GW, Sinclair J, Sissons JG. 2005. Human cytomegalovirus encodes an MHC class I-like molecule (UL142) that functions to inhibit NK cell lysis. J. Immunol. 175:7457-7465.
33. Umashankar M, Petrucelli A, Cicchini L, Caposio P, Kreklywich CN, Rak M, Bughio F, Goldman DC, Hamlin KL, Nelson JA, Fleming WH, Streblow DN, Goodrum F. 2011. A novel human cytomegalovirus locus modulates cell type-specific outcomes of infection. PLoS Pathog. 7:e1002444. doi:10.1371/journal.ppat.1002444.
34. Loewendorf A, Benedict CA. 2010. Modulation of host innate and adaptive immune defenses by cytomegalovirus: timing is everything. J. Intern. Med. 267:483-501.
35. Quinnan GV, Jr, Rook AH. 1984. The importance of cytotoxic cellular immunity in the protection from cytomegalovirus infection. Birth Defects Orig. Artic. Ser. 20:245-261.
36. Simon CO, Seckert CK, Dreis D, Reddehase MJ, Grzimek NK. 2005. Role for tumor necrosis factor alpha in murine cytomegalovirus transcriptional reactivation in latently infected lungs. J. Virol. 79:326-340.
37. Benedict CA, Butrovich KD, Lurain NS, Corbeil J, Rooney I, Schneider P, Tschopp J, Ware CF. 1999. A novel viral TNF receptor superfamily member in virulent strains of human cytomegalovirus. J. Immunol. 162: 6967-6970.
38. Montgomery RI, Warner MS, Lum BJ, Spear PG. 1996. Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family. Cell 87:427-436.
39. Lurain NS, K K, Huang DD, Short JA, Paintsil J, Winkfield E, Benedict CA, Ware CF, Bremer JW. 1999. Human cytomegalovirus UL144 open reading frame: sequence hypervariability in low-passage clinical isolates. J. Virol. 73:10040-10050.
40. Nakayama Y, Abe H, Rapaport FT, Waltzer WC, Kakita A. 1994. Influence of donor factors other than serologic status on transmission of cytomegalovirus to renal transplant recipients. Transplant Proc. 26:936-937.
41. Cheung TC, Humphreys IR, Potter KG, Norris PS, Shumway HM, Tran BR, Patterson G, Jean-Jacques R, Yoon M, Spear PG, Murphy KM, Lurain NS, Benedict CA, Ware CF. 2005. Evolutionarily divergent herpesviruses modulate T cell activation by targeting the herpesvirus entry mediator cosignaling pathway. Proc. Natl. Acad. Sci. U. S. A. 102:13218-13223.
42. Ware CF, VanArsdale TL, Crowe PD, Browning J. 1995. The ligands and receptors of the lymphotoxin system. Curr. Top. Microbiol. Immunol. 198:175-218.
43. Goormachtigh G, Ouk TS, Mougel A, Tranchand-Bunel D, Masy E, LeClorennec C, Feuillard J, Bornkamm GW, Auriault C, Manet E, Fafeur V, Adriaenssens E, Coll J. 2006. Autoactivation of the Epstein-Barr virus oncogenic protein LMP1 during type II latency through opposite roles of the NF-kappaB and JNK signaling pathways. J. Virol. 80:7382-7393.
44. Takegawa S, Jin Z, Nakayama T, Oyama T, Hieshima K, Nagakubo D, Shirakawa AK, Tsuzuki T, Nakamura S, Yoshie O. 2008. Expression of CCL17 and CCL22 by latent membrane protein 1-positive tumor cells in age-related Epstein-Barr virus-associated B-cell lymphoproliferative disorder. Cancer Sci. 99:296-302.
45. Poole E, McGregor Dallas SR, Colston J, Joseph RS, Sinclair J. 2011. Virally induced changes in cellular microRNAs maintain latency of human cytomegalovirus in CD34 progenitors. J. Gen. Virol. 92:1539-1549.
46. Waller EC, Day E, Sissons JG, Wills MR. 2008. Dynamics of T cell memory in human cytomegalovirus infection. Med. Microbiol. Immunol. 197:83-96.
47. Griffin C, Wang EC, McSharry BP, Rickards C, Browne H, Wilkinson GW, Tomasec P. 2005. Characterization of a highly glycosylated form of the human cytomegalovirus HLA class I homologue gpUL18. J. Gen. Virol. 86:2999-3008.
48. Poole E, Strappe P, Mok HP, Hicks R, Lever AML. 2005. HIV-1 gag-RNA interaction occurs at a perinuclear/centrosomal site: analysis by confocal microscopy and FRET. Traffic 6:1-15.
49. Groves IJ, Reeves MB, Sinclair JH. 2009. Lytic infection of permissive cells with human cytomegalovirus is regulated by an intrinsic 'preimmediate- early' repression of viral gene expression mediated by histone post-translational modification. J. Gen. Virol. 90:2364-2374.
50. Reeves MB, Compton T. 2011. Inhibition of inflammatory interleukin-6 activity via extracellular signal-regulated kinase-mitogen-activated protein kinase signaling antagonizes human cytomegalovirus reactivation from dendritic cells. J. Virol. 85:12750-12758.
51. Taylor-Wiedeman J, Sissons JG, Borysiewicz LK, Sinclair JH. 1991. Monocytes are a major site of persistence of human cytomegalovirus in peripheral blood mononuclear cells. J. Gen. Virol. 72(Part 9):2059-2064.
52. Murayama T, Takegoshi M, Tanuma J, Eizuru Y. 2005. Analysis of human cytomegalovirus UL144 variability in low-passage clinical isolates in Japan. Intervirology 48:201-206.
53. Campos EI, Reinberg D. 2009. Histones: annotating chromatin. Annu. Rev. Genet. 43:559-599.
54. Reeves M, Murphy J, Greaves R, Fairley J, Brehm A, Sinclair J. 2006. Autorepression of the human cytomegalovirus major immediate-early promoter/enhancer at late times of infection is mediated by the recruitment of chromatin remodeling enzymes by IE86. J. Virol. 80:9998-10009.
55. Tsai FY, Keller G, Kuo FC, Weiss M, Chen J, Rosenblatt M, Alt FW, Orkin SH. 1994. An early haematopoietic defect in mice lacking the transcription factor GATA-2. Nature 371:221-226.
56. Tsai FY, Orkin SH. 1997. Transcription factor GATA-2 is required for proliferation/survival of early hematopoietic cells and mast cell formation, but not for erythroid and myeloid terminal differentiation. Blood 89: 3636-3643.
57. Vicente C, Conchillo A, Garcia-Sanchez MA, Odero MD. 2011. The role of the GATA2 transcription factor in normal and malignant hematopoiesis. Crit. Rev. Oncol. Hematol. 82:1-17.
58. Sinclair JH, Baillie J, Bryant LA, Taylor-Wiedeman JA, Sissons JG. 1992. Repression of human cytomegalovirus major immediate early gene expression in a monocytic cell line. J. Gen. Virol. 73(Part 2):433-435.
59. Bego MG, St Jeor S. 2006. Human cytomegalovirus infection of cells of hematopoietic origin: HCMV-induced immunosuppression, immune evasion, and latency. Exp. Hematol. 34:555-570.
60. Wilson NK, Foster SD, Wang X, Knezevic K, Schutte J, Kaimakis P, Chilarska PM, Kinston S, Ouwehand WH, Dzierzak E, Pimanda JE, de Bruijn MF, Gottgens B. 2010. Combinatorial transcriptional control in blood stem/progenitor cells: genome-wide analysis of ten major transcriptional regulators. Cell Stem Cell 7:532-544.
61. Nakayama T, Hieshima K, Nagakubo D, Sato E, Nakayama M, Kawa K, Yoshie O. 2004. Selective induction of Th2-attracting chemokines CCL17 and CCL22 in human B cells by latent membrane protein 1 of Epstein-Barr virus. J. Virol. 78:1665-1674.
62. Slobedman B, Mocarski ES. 1999. Quantitative analysis of latent human cytomegalovirus. J. Virol. 73:4806-4812.
63. Cheung TC, Oborne LM, Steinberg MW, Macauley MG, Fukuyama S, Sanjo H, D'Souza C, Norris PS, Pfeffer K, Murphy KM, Kronenberg M, Spear PG, Ware CF. 2009. T cell intrinsic heterodimeric complexes between HVEM and BTLA determine receptivity to the surrounding microenvironment. J. Immunol. 183:7286-7296.
64. Pignatelli S, Dal Monte P. 2009. Epidemiology of human cytomegalovirus strains through comparison of methodological approaches to explore gN variants. New Microbiol. 32:1-10.
65. Arav-Boger R, Battaglia CA, Lazzarotto T, Gabrielli L, Zong JC, Hayward GS, Diener-West M, Landini MP. 2006. Cytomegalovirus (CMV)- encoded UL144 (truncated tumor necrosis factor receptor) and outcome of congenital CMV infection. J. Infect. Dis. 194:464-473.
66. Arav-Boger R, Willoughby RE, Pass RF, Zong JC, Jang WJ, Alcendor D, Hayward GS. 2002. Polymorphisms of the cytomegalovirus (CMV)- encoded tumor necrosis factor-alpha and beta-chemokine receptors in congenital CMV disease. J. Infect. Dis. 186:1057-1064.
67. Picone O, Costa JM, Chaix ML, Ville Y, Rouzioux C, Leruez-Ville M. 2005. Human cytomegalovirus UL144 gene polymorphisms in congenital infections. J. Clin. Microbiol. 43:25-29.
68. Picone O, Costa JM, Ville Y, Chaix ML, Rouzioux C, Leruez-Ville M. 2004. Genetic polymorphism of cytomegalovirus strains responsible of congenital infections. Pathol. Biol. (Paris) 52:534-539. (In French.)
69. Yan H, Koyano S, Inami Y, Yamamoto Y, Suzutani T, Mizuguchi M, Ushijima H, Kurane I, Inoue N. 2008. Genetic variations in the gB, UL144 and UL149 genes of human cytomegalovirus strains collected from congenitally and postnatally infected Japanese children. Arch. Virol. 153: 667-674.